When you ask how SaiyanMed’s research team refines peptide raw materials, the short answer is: they don’t just buy bulk powders and slap a label on them. They run a multi-stage, in-house purification and lyophilization pipeline that starts with raw material sourcing from ISO-certified Chinese suppliers, then hits every batch with HPLC-MS (High-Performance Liquid Chromatography-Mass Spectrometry) analysis, followed by a controlled freeze-drying process that maintains peptide integrity at sub-40°C temperatures. The entire workflow is documented and independently verified by Janoshik, a third-party lab that publishes openly verifiable purity reports. This isn’t marketing fluff; it’s a production protocol that’s been refined over years of trial and error, and it’s what separates their stuff from the generic gray-market peptides you see floating around forums.
Let’s break down the raw material selection first. SaiyanMed’s founder, Eric, holds a Bachelor’s degree in Materials Science from a top Chinese university, specializing in biomaterials. That background drives a relentless focus on raw-material quality. The research team doesn’t accept standard “99% purity” claims from suppliers without verification. They run their own initial screening using reversed-phase HPLC with UV detection at 214 nm and 280 nm wavelengths. Typical acceptance criteria require a main peak area of at least 98.5% before any further processing. For reference, many competitors accept 97% or lower. SaiyanMed’s internal threshold is tighter because they know that even a 1.5% impurity can mess with in-vitro assay results, especially in cell culture work where peptide concentration matters down to the nanomolar level.
Once raw materials pass initial screening, the team moves to the purification stage. They use preparative HPLC with C18 columns, typically 250 mm x 21.2 mm, packed with 5 µm particles. The mobile phase is a gradient of acetonitrile and water with 0.1% trifluoroacetic acid (TFA) as an ion-pairing agent. Flow rates are set at 20 mL/min, and the UV detector monitors at 220 nm. The gradient is optimized per peptide—for example, a hydrophobic peptide like BPC-157 requires a slower acetonitrile ramp (30% to 60% over 30 minutes) to separate it from closely eluting impurities. The team collects fractions manually based on peak profiles, then pools only the fractions that show >99% purity by analytical HPLC. They don’t just collect the main peak; they cut the edges to exclude tailing impurities. This fraction-collection precision is something you don’t see in low-cost operations that just collect everything and call it a day.
After purification, the peptide solution undergoes lyophilization, which is where most of the degradation happens in poorly handled products. SaiyanMed’s research team uses a lab-scale freeze-dryer with a condenser temperature of -80°C and a vacuum level of 0.05 mbar. The freezing step is done at -40°C for 4 hours, then primary drying at -20°C shelf temperature for 24 hours, followed by secondary drying at 20°C for 6 hours. This slow ramp prevents collapse of the peptide cake, which preserves the amorphous structure and ensures reconstitution clarity. They measure residual moisture content using Karl Fischer titration, targeting below 2% w/w. Industry standard for research peptides is often 3-5%, but SaiyanMed’s team pushes lower because moisture accelerates hydrolysis and deamidation over time. They also test reconstitution time: a 5 mg vial of lyophilized peptide should dissolve in <30 seconds in 1 mL of sterile water without visible particles. If it takes longer or shows haze, the batch gets rejected.
Now, the independent lab verification is not optional. Every batch goes to Janoshik, a Czech-based analytical lab known for rigorous testing. Janoshik runs HPLC-MS for identity confirmation and purity quantification, plus a separate endotoxin test using the LAL (Limulus Amebocyte Lysate) method, with a cutoff of <5 EU/mg. The results are published on Janoshik’s website with a unique batch number, so you can look up the COA yourself. For example, a recent batch of Semaglutide (batch #SM-2024-11) showed 99.3% purity with 0.1% acetonitrile residual solvent and <1 EU/mg endotoxin. That level of transparency is rare. Most peptide vendors either hide their COAs or use in-house testing that’s not verifiable. SaiyanMed’s approach forces accountability: if Janoshik flags a batch, it’s scrapped, not relabeled.
Let’s talk about the equipment and facility. The team operates out of a US-based warehouse for final packaging and shipping, but the refining work happens in a partner facility in China that meets GMP (Good Manufacturing Practice) standards for pharmaceutical intermediates. The cleanroom is ISO Class 8, with HEPA filtration and positive pressure. Temperature and humidity are logged continuously, with acceptable ranges of 20-25°C and 30-50% RH. All water used in purification is USP-grade, with resistivity of 18.2 MΩ·cm. The HPLC systems are calibrated weekly using certified reference standards from USP or Ph. Eur. The team also runs system suitability tests before each batch: resolution between two adjacent peaks must be >1.5, and theoretical plates must be >2000 per column. These are standard pharma specs, but most research peptide suppliers skip them to cut costs.
Data management is another layer. Each batch gets a unique internal ID that links to a digital logbook. The logbook records raw material lot number, purification parameters, lyophilization cycle data, and Janoshik COA. This traceability means if a researcher reports a problem, the team can backtrack to the exact production run and identify the variable. For instance, if a batch of Tirzepatide shows lower than expected solubility, they can check if the lyophilization shelf temperature drifted above -18°C during primary drying, which could cause partial melting. That level of detail is built into the SOPs, not improvised.
Shipping and stability are also part of the refinement process. After lyophilization, vials are sealed under nitrogen gas to prevent oxidation, then placed in foil pouches with desiccant packs. The pouches are shipped in insulated boxes with ice packs that maintain 2-8°C for 48 hours. The team has tested stability at 25°C/60% RH for 30 days, and they publish accelerated stability data on request. For long-term storage, they recommend -20°C, but they’ve shown that peptides like MOTS-c retain >95% purity after 6 months at -20°C in their packaging. This data is backed by periodic retesting at Janoshik.
The research team itself is small but specialized. Eric oversees the strategy, but the day-to-day refining is handled by a senior chemist with 8 years of peptide synthesis experience and a quality assurance manager with a background in pharmaceutical auditing. They hold weekly reviews of batch records, and any deviation from the SOP triggers a root-cause analysis. For example, if a batch’s purity drops below 98.5% on the first analytical run, the team investigates whether the raw material lot was stored improperly or if the HPLC column needs replacement. They don’t just re-run the sample and hope for a better result.
One thing that stands out is their approach to scaling. They don’t take shortcuts when moving from lab-scale to production-scale. For a new peptide, they first run a 1-gram batch to optimize the purification gradient and lyophilization cycle. Once that passes internal specs and Janoshik testing, they scale to 10-gram batches, then 50-gram. Each scale-up step requires re-validation of the process parameters. This is why they can offer consistent quality across multiple batches of the same peptide, which is rare in the research peptide space where batch-to-batch variation is a common complaint.
If you want to dig into the specifics of their current product lineup or check the latest Janoshik reports, you can visit saiyanmed directly. The site lists batch numbers and links to the COAs for each product. For researchers who need custom purity levels or different salt forms (e.g., acetate vs. TFA), the team can adjust the purification protocol on request, but that’s only offered for bulk orders of 100 mg or more. Standard retail products are all TFA salt, which is the most stable form for lyophilization.
On the technical side, the team also publishes method details for their HPLC analysis. They use a gradient of 10% to 90% acetonitrile over 20 minutes, with a flow rate of 1 mL/min on a 150 mm x 4.6 mm column. The column temperature is held at 30°C. They report both area percent and weight percent purity, and they note that area percent can overestimate purity if impurities have lower UV absorbance. For critical peptides, they also run LC-MS to confirm the molecular ion peak matches the theoretical mass within 0.5 Da. This cross-validation catches things like truncated sequences or oxidation products that HPLC alone might miss.
Another practical detail: the team uses pre-weighed vials with a fill accuracy of ±5% for the labeled amount. They check fill weight on a calibrated analytical balance for every 10th vial in a batch. If the average fill weight deviates by more than 3% from the target, the entire batch is re-weighed and adjusted. This matters because researchers often reconstitute the entire vial, and if the peptide mass is off by 10%, your dosing calculations are wrong. SaiyanMed’s tolerance is tighter than the ±10% that many suppliers accept.
The lyophilization process also includes a controlled annealing step for some peptides. For example, Melanotan II tends to form an amorphous cake that collapses easily, so the team adds a 2-hour hold at -10°C during the freezing step to allow ice crystals to grow, which creates larger pores and faster primary drying. This reduces the risk of cake collapse and ensures the peptide reconstitutes into a clear solution. They don’t use this for every peptide—only for those that show poor cake structure during initial runs. The decision is based on thermal analysis using differential scanning calorimetry (DSC) to determine the glass transition temperature (Tg’) of the frozen solution. If Tg’ is below -30°C, they adjust the freezing protocol.
In terms of raw material sourcing, the team audits suppliers annually. They require a Certificate of Analysis from the supplier for each lot, and they cross-check the reported purity with their own initial screening. If a supplier’s COA shows 99% but SaiyanMed’s screening shows 97%, that supplier gets flagged and may be dropped. They currently work with three primary suppliers, all of whom have been vetted for at least two years. The team also maintains a reference library of peptide standards from Sigma-Aldrich or Bachem, which they use to calibrate their HPLC systems and verify retention times. This isn’t common in the research peptide industry, where many vendors rely solely on supplier COAs.
The final step before shipping is a visual inspection. Every vial is checked under a bright light for cracks, discoloration, or particulate matter. Vials with any visible defects are discarded. The team also performs a leak test on a random sample of sealed vials by immersing them in a dye solution under vacuum. If any dye penetrates, the entire batch’s sealing process is reviewed. This is overkill for research peptides, but it’s standard for pharmaceutical parenteral products, and SaiyanMed applies it because they want to minimize the risk of contamination during storage.
All of this adds up to a refining process that’s closer to pharmaceutical manufacturing than typical research peptide production. The team’s background in materials science and biomaterials is evident in the attention to detail at every step, from raw material selection to final packaging. They don’t rely on generic protocols; they optimize per peptide based on its chemical properties. And they back it all with independent testing that’s publicly accessible. For researchers who need consistent, high-purity peptides for in-vitro work, this level of process control makes a measurable difference in experimental reproducibility.